Vitamin receptor binding drug delivery conjugates

Details Vitamin receptor binding drug delivery conjugates Vitamin receptor binding drug delivery conjugates

2004-01-27

2009-10-13

Jones, D. L (Department: 1618)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S001110, C424S001650, C424S009100

Reexamination Certificate

active

07601332

ABSTRACT:
The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

REFERENCES:
patent: 2816110 (1957-12-01), Sletzinger et al.
patent: 4691024 (1987-09-01), Sirahata
patent: 4713249 (1987-12-01), Schroder
patent: 5140104 (1992-08-01), Coughlin et al.
patent: 5266333 (1993-11-01), Cady
patent: 5417982 (1995-05-01), Modi
patent: 5552545 (1996-09-01), Pearce et al.
patent: 5672486 (1997-09-01), Soulillou
patent: 5998603 (1999-12-01), Cook
patent: 6030941 (2000-02-01), Summerton et al.
patent: 6056973 (2000-05-01), Allen
patent: 6077499 (2000-06-01), Griffiths
patent: 6335434 (2002-01-01), Guzaev et al.
patent: 6596757 (2003-07-01), Chari et al.
patent: 7067111 (2006-06-01), Yang et al.
patent: 7128893 (2006-10-01), Leamon et al.
patent: WO 99/61055 (1999-12-01), None
patent: WO 00/35422 (2000-06-01), None
patent: PCT/US2008/054189 (2008-02-01), None
patent: PCT/US2008/056824 (2008-03-01), None
patent: PCT/US2008068093 (2008-06-01), None
Lu et al, Cancer Immunology Immunotherapy, Mar. 2002, vol. 51, No. 3, pp. 153-162.
Punj, Vasu; Graves, Jewell M.; Mehta, Rajeshwari R.; “Effect of Vitamin D Analog (1α Hydroxy D5) Immunoconjugated to Her-2 Antibody on Breast Cancer,” Int. J. Cancer, 108, 922-929, 2004.
Anderson et al., “Potocytosis: Sequestration and transport of small molecules by caveolae,”Science255: 410-411 (1992).
Antony, A. C., “Folate receptors,”Annu Rev Nutr, 16: 501-21 (1996).
Antony, A. C., “The biological chemistry of folate receptors,”Blood79(11):2807-2820 (1992).
Barnett et al., “Structure-Activity Relationships of Dimeric Catharanthus Alkaloids. 1. Deacetylvinblastine Amide (Vindesine) Sulfate,”J. Med. Chem. 21: 88-96 (1978).
Boger, D.L., et al., “1,2,9,9a-Tetrahydrocyclopropa[ c ]benz[ ε]indol-4-one (CBI): A Simplified Analogue of the CC-1065 Alkylation Subunit,”J. Org. Chem. 57: 2873-2876 (1992).
Campbell et al., “Folate-binding protein is a marker for ovarian cancer,”Cancer Res. 51: 5329-5338 (1991).
Cho et al., “Single-chain Fv/folate conjugates mediate efficient lysis of folate-receptor-positive tumor cells,”Bioconjug. Chem. 8(3): 338-346 (1997).
Christensen et al., “Membrane receptors for endocytosis in the renal proximal tubule,”Int. Rev. Cytol. 180: 237-284 (1998).
Citro, et al., “Inhibition of leukemia cell proliferation by folic acid—polylysine-mediated introduction of c-mybantisense oligodeoxynucelotides into HL-60 cells,”Br. J. Cancerl, 69, 463-467, (1994).
Frankel, A.E., “Immunotoxin therapy of cancer,”Oncology7: 69 (1993).
Garin-Chesa et al., “Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein,”Am. J. Pathol. 142(2): 557-562 (1993).
Gottschalk, S., et al., “Folate receptor mediated DNA delivery into tumor cells: potosomal disruption results in enhanced gene expression,”Gene Therapy1(3): 185-191 (1994).
Hofland et al., “Folate-targeted gene transfer in vivo,”Mol Ther5(6): 739-744 (2002).
Holladay et al., “Riboflavin-mediated delivery of a macromolecule into cultured human cells,”Biochim Biophys Acta1426(1): 195-204 (1999).
Holm, J., et al., “Folate receptors in malignant and benign tissues of human female genital tract,”BioSci. Rep. 17(4): 415-427 (1997).
Holm, J., et al., “High-affinity folate binding in human choroid plexus. Characterization of radioligand binding, immunoreactivity, molecular heterogeneity and hydrophobic domain of the binding protein,”Biochem J.280(1): 267-271 (1991).
Kamen et al., “Delivery of folates to the cytoplasm fo MA104 cells is mediated by a surface receptor that recycles,”J. Biol. Chem. 263: 13602-13609 (1988).
Kamen, B. A. and Capdevila, A., “Receptor-mediated folate accumulation is regulated by the cellular folate content,”Proc. Natl. Acad. Sci. USA83: 5983-5987 (1986).
Kamen et al., “The folate receptor works in tandem with a probenecid-sensitive carrier in MA104 cells in vitro,”J. Clin. Invest. 87(4): 1442-1449 (1991).
Kane et al., “The influence of extracellular folate concentration on methotrexate uptake by human KB cells. Partial characterization of a membrane-associated methotrexate binding protein,”J. Biol. Chem. 261: 44-49 (1986).
Kranz et al., “Conjugates of folate and anti-T-cell-receptor antibodies specifically target folate-receptor-positive tumor cells for lysis,”Proc. Natl. Acad. Sci. USA92(20), 9057-9061 1995.
Ladino et al., “Folate-maytansinoids: target-selective drugs of low molecular weight,”Int. J. Cancer73(6): 859 864 (1997).
Leamon, C. P. and Low, P. S., “Folate-mediated targeting: from diagnostics to drug and gene delivery,”Drug Discovery Today6: 36-43 (2001).
Leamon, C. P. and Low, P. S, “Cytotoxicity of momordin-folate conjugates in cultured human cells,”J. Biol. Chem. 267(35): 24966-24971 (1992).
Leamon, C. P. and Low, P. S, “Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis,”Proc. Natl. Acad. Sci. USA88(13): 5572-5573 (1991).
Leamon, C. P. and Low, P. S, “Membrane folate-binding proteins are responsible for folate-protein conjugate endocytosis into cultured cells,”Biochem. J. 291: 855-860 (1993).
Leamon, C. P. and Low, P. S, “Selective targeting of malignant cells with cytotoxin-folate conjugates,”J. Drug Target. 2(2): 101-112 (1994).
Leamon et al., “Folate-mediated drug delivery: effect of alternative conjugation chemistry,”J. Drug Target7(3): 157-169 (1999).
Leamon et al., “Synthesis and Biological Evaluation of EC20: A New Folate-Derived, (99m)Tc-Based Radiopharmaceutical,”Bioconjug. Chem. 13(6): 1200-1210 (2002).
Leamon et al, “Cytotoxicity of folate-Pseudomonas exotoxin conjugates toward tumor cells. Contribution of translocation domain,”J. Biol. Chem. 268(33): 24847-24854 (1993).
Lee et al., “Synthesis and evaluation of taxol-folic acid conjugates as targeted antineoplastics,”Bioorg Med Chem. 10(7): 2397-2414, (2002).
Lee, R. J. and Huang, L., “Folate-Targeted, Anionic Liposome-Entrapped Polylysine-Condensed Dna For Tumor Cell-Specific Gene Transfer,”J. Biol. Chem. 271(14): 8481-8487 (1996).
Lee, R. J. and Low, P. S., “Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro,”Biochim. Biophys. Acta1233: 134-144 (1995).
Lee, R. J. and Low, P. S, “Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis,”J. Biol. Chem. 269(5): 3198-3204 (1994).
Lee et al, “Measurement of Endosome pH Following Folate Receptor-Mediated Endocytosis,”Biochim. Biophys. Acta1312(3): 237-242 (1996).
Lewis et al., “Receptor-mediated folate uptake is positively regulated by disruption of actin cytoskeleton,”Cancer Res. 58(14): 2952-2956 (1998).
Liu et al., “Targeted Drug Delivery to Chemoresistant Cells: Folic Acid Derivatization of FdUMP[10] Enhances Cytotoxicity Toward 5-FU-Resistant Human Colorectal Tumor Cells,”J

Affiliated with

Also associated with

Rating

Vitamin receptor binding drug delivery conjugates does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Vitamin receptor binding drug delivery conjugates, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vitamin receptor binding drug delivery conjugates will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4143080